Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CLVS
Previous Symbol
CUSIP18946410
Phone303-625-5000
Debt
Debt-to-Equity Ratio2.46
Current Ratio9.03
Quick Ratio8.46
Price-To-Earnings
Trailing P/E Ratio-4.05
Forward P/E Ratio-3.05
P/E GrowthN/A
Sales & Book Value
Annual Sales$55.51 million
Price / Sales19.71
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.50 per share
Price / Book2.77
Profitability
EPS (Most Recent Fiscal Year)($5.12)
Net Income$-346,390,000.00
Net Margins-390.65%
Return on Equity-108.92%
Return on Assets-40.59%
Miscellaneous
Employees360
Outstanding Shares52,710,000
Market Cap$1.10 billion
OptionableOptionable
Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology (NASDAQ:CLVS) issued its earnings results on Tuesday, October, 30th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.60) by $0.11. The biopharmaceutical company had revenue of $22.76 million for the quarter, compared to analyst estimates of $30.11 million. Clovis Oncology had a negative return on equity of 108.92% and a negative net margin of 390.65%. The firm's revenue for the quarter was up 35.4% on a year-over-year basis. During the same period last year, the company posted ($1.24) earnings per share. View Clovis Oncology's Earnings History.
When is Clovis Oncology's next earnings date?
What price target have analysts set for CLVS?
13 brokers have issued 12 month price objectives for Clovis Oncology's shares. Their forecasts range from $16.00 to $110.00. On average, they anticipate Clovis Oncology's stock price to reach $57.0520 in the next year. This suggests a possible upside of 174.8% from the stock's current price. View Analyst Price Targets for Clovis Oncology.
What is the consensus analysts' recommendation for Clovis Oncology?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clovis Oncology.
What are Wall Street analysts saying about Clovis Oncology stock?
Here are some recent quotes from research analysts about Clovis Oncology stock:
- 1. According to Zacks Investment Research, "Clovis’ Rubraca is progressing well and registering sales growth. Nonetheless, Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Moreover, Clovis received approval for the label expansion in second-line maintenance setting in the United States, irrespective of BRCA-mutation, and as monotherapy in Europe. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. The company has stopped development of rociletinib upon receiving a CRL and lucitanib on negative results. Any further setback will adversely affect the company’s prospects. Moreover, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Meanwhile, Rubraca is set to face intense competition from currently marketed PARP inhibitors. Clovis’ shares have underperformed the industry so far this year." (7/10/2018)
- 2. JPMorgan Chase & Co. analysts commented, "2018 Procedure Growth Guidance Should Help Shares ISRG reported preliminary 4Q17 revenue of $892M (18% y/y), above our forecast of $865M and consensus’ estimates of $847M. Procedure growth of 17% came in higher than our 16.2% estimate and the Street’s 15.1% forecast. The sales breakout for 4Q included $457 in instrument revenue, $283 in system sales, and $153 for service, higher than our and Street estimates in each segment. 2018 guidance calls for 11-15% procedure growth, above our 10.9% forecast and in-line with consensus growth of 12.8%. This beat on revenue and procedure growth matched our expectations going into the report. Stellar revenue, strong procedure growth, and in-line 2018 guidance should boost shares today. There were 216 systems shipped in the quarter, well above our 180 unit estimate and the Street’s 187. Of these, 40 were shipped under operating lease agreements. However, implied system ASPs were $1.31M, below our modeled $1.55M and a more than $200Ksequential decline from Q3." (1/11/2018)
Has Clovis Oncology been receiving favorable news coverage?
News articles about CLVS stock have been trending somewhat negative on Friday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Clovis Oncology earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the stock's share price in the next few days.
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include Loxo Oncology (LOXO), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), FibroGen (FGEN), Array Biopharma (ARRY), Horizon Pharma (HZNP), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Evotec (EVTCY), Akcea Therapeutics (AKCA), Ascendis Pharma A/S (ASND) and Allakos (ALLK).
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
- Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
- Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
- Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
- Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)
Who are Clovis Oncology's major shareholders?
Clovis Oncology's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.43%), Vanguard Group Inc (8.43%), Redmile Group LLC (3.37%), Alliancebernstein L.P. (2.68%), Macquarie Group Ltd. (1.67%) and Capital World Investors (1.01%). Company insiders that own Clovis Oncology stock include Gillian C Ivers-Read, James C Blair, Lindsey Rolfe and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.
Which major investors are selling Clovis Oncology stock?
CLVS stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Capital World Investors, Man Group plc, Los Angeles Capital Management & Equity Research Inc., Point72 Asset Management L.P., C WorldWide Group Holding A S, Russell Investments Group Ltd. and Wealthstreet Investment Advisors LLC. Company insiders that have sold Clovis Oncology company stock in the last year include Gillian C Ivers-Read, Lindsey Rolfe and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.
Which major investors are buying Clovis Oncology stock?
CLVS stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Macquarie Group Ltd., Perceptive Advisors LLC, Capital International Investors, Vanguard Group Inc, Vanguard Group Inc., Opus Point Partners Management LLC and Marshall Wace North America L.P.. View Insider Buying and Selling for Clovis Oncology.
How do I buy shares of Clovis Oncology?
Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of CLVS stock can currently be purchased for approximately $20.76.
How big of a company is Clovis Oncology?
Clovis Oncology has a market capitalization of $1.10 billion and generates $55.51 million in revenue each year. The biopharmaceutical company earns $-346,390,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Clovis Oncology employs 360 workers across the globe.
What is Clovis Oncology's official website?
How can I contact Clovis Oncology?
Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]
MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
